Risperdal ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 203 | 22q11.2 deletion syndrome | 1 |
203. 22q11.2 deletion syndrome
Clinical trials : 5 / Drugs : 7 - (DrugBank : 1) / Drug target genes : 14 - Drug target pathways : 23
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04639960 (ClinicalTrials.gov) | September 29, 2017 | 3/11/2020 | Neuroprotective Effects of Risperdal on Brain and Cognition in 22q11 Deletion Syndrome | Effects of Modulation of the Dopaminergic System Using Risperidone on Memory and Executive Processes in Individuals With 22q11.2 Deletion Syndrome | 22q11.2 Deletion Syndrome | Drug: Risperdal;Drug: Placebo | University of Geneva, Switzerland | NULL | Terminated | 11 Years | 25 Years | All | 16 | N/A | Switzerland |